What does this video actually claim?
@alaysha.hurd announces she's starting a "peptide journey" using GHK-Cu, MT-2, and retatrutide. The 95.3K-view TikTok doesn't make specific health claims but promotes these three compounds as part of her wellness routine.
The video is light on details but heavy on influence. She's essentially endorsing a three-peptide stack to her followers without explaining what each compound does or their legal status. This matters because two of these aren't FDA-approved for human use.
Are these peptides actually safe and legal?
Only one of the three peptides she mentions has solid human safety data. GHK-Cu appears in cosmetic products and has some wound healing research, though studies are small. A 2012 study by Pickart et al. found GHK-Cu improved skin appearance in 71 women over 12 weeks.
MT-2 (melanotan II) is where things get sketchy. The FDA has issued multiple warnings about melanotan products sold online. The agency found cases of nausea, decreased appetite, and darkened skin patches. There's no approved version for cosmetic tanning.
Retatrutide is experimental. Eli Lilly's phase 2 trial (Jastreboff et al., NEJM, 2023) showed 24.2% weight loss at 48 weeks with the 12mg dose, but it's not FDA-approved. You can't legally obtain it outside clinical trials.
What did she get wrong about these compounds?
The biggest issue is promoting retatrutide like it's available for general use. It's not. The compound is still in clinical development, and Eli Lilly controls the supply for research purposes only.
She also skips the side effect discussion entirely. The retatrutide trial reported nausea in 65.6% of participants at the highest dose. That's not exactly Instagram-friendly content, but followers deserve to know.
For MT-2, she's promoting a compound that regulatory agencies actively warn against. The TGA in Australia and MHRA in the UK have both issued safety alerts about melanotan products causing serious adverse reactions.
What should you actually know about peptide therapy?
Most "peptide therapy" exists in a regulatory gray area. Compounding pharmacies sell many peptides for research purposes, but doctors prescribing them off-label don't always have strong safety data to work with.
GHK-Cu has the best safety profile of the three, but even here the evidence is thin. Most studies use topical applications, not injections. The concentration matters too, and influencers rarely specify dosing details.
If you're interested in evidence-based alternatives, FDA-approved GLP-1 medications like semaglutide and tirzepatide offer proven weight management benefits. The SURMOUNT-1 trial showed 22.5% weight loss with tirzepatide at 84 weeks. That's comparable to retatrutide without the legal issues.